US 12,310,992 · Application 18/535,745 · Granted May 27, 2025
US 12,310,992
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
Estimated expiration
July 30, 2033
6y 305d remaining
Earliest effective filing
Jul 30, 2013
+ 20 years
Jul 30, 2033
PTA +0d
Jul 30, 2033
TD applied
Jul 30, 2033
Final
Jul 30, 2033
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- December 11, 2023
- Earliest effective filing
- July 30, 2013
- Issue date
- May 27, 2025
- PTA
- 0 days
- Base expiry (before PTA)
- July 30, 2033
July 30, 2013 + 20 years = July 30, 2033
- Divisional of application 17/072,430, filed Oct 16, 2020, issued as US 11,839,631
- Continuation of application 16/002,250, filed Jun 7, 2018, issued as US 10,842,823
- Divisional of application 14/418,557, filed Jan 30, 2015, issued as US 10,016,463
- National stage entry of application PCTUS2013052700, filed Jul 30, 2013
- National stage entry of application PCTUS2013052700, filed Jul 30, 2013
- Divisional of application 14/418,557, filed Jan 30, 2015, issued as US 10,016,463
- National stage entry of application PCTUS2013052700, filed Jul 30, 2013
- Continuation of application 16/002,250, filed Jun 7, 2018, issued as US 10,842,823
- Divisional of application 14/418,557, filed Jan 30, 2015, issued as US 10,016,463
- National stage entry of application PCTUS2013052700, filed Jul 30, 2013
- PRO61/678,208 — Provisional — not used for base term
- PRO61/750,458 — Provisional — not used for base term
- PRO61/678,208 — Provisional — not used for base term
- PRO61/750,458 — Provisional — not used for base term
- PRO61/678,208 — Provisional — not used for base term
- PRO61/750,458 — Provisional — not used for base term
- PRO61/678,208 — Provisional — not used for base term
- PRO61/750,458 — Provisional — not used for base term
- PRO61/678,208 — Provisional — not used for base term
- PRO61/750,458 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to July 30, 2033
US 11,141,393· Application 16/137,629Capping patent
Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
- Filing date
- Sep 21, 2018
- Earliest effective filing
- Jan 8, 2014
- Issue date
- Oct 12, 2021
- PTA
- +107 days
- Calculated expiration
- Apr 25, 2034
Divisional of 14/149,929, filed Jan 8, 2014, issued as US 10,080,730
Jan 8, 2014 + 20y + 107d PTA = Apr 25, 2034
US 10,016,463· Application 14/418,557Capping patent
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
- Filing date
- Jan 30, 2015
- Earliest effective filing
- Jul 30, 2013
- Issue date
- Jul 10, 2018
- PTA
- +93 days
- Calculated expiration
- Oct 31, 2033
National stage entry of PCTUS2013052700, filed Jul 30, 2013
Jul 30, 2013 + 20y + 93d PTA = Oct 31, 2033
US 12,310,992· Application 18/535,745(from application 18/535,745)Capping patent
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
- Filing date
- Dec 11, 2023
- Earliest effective filing
- Jul 30, 2013
- Issue date
- May 27, 2025
- PTA
- 0 days
- Calculated expiration
- Jul 30, 2033
Divisional of 17/072,430, filed Oct 16, 2020, issued as US 11,839,631
Continuation of 16/002,250, filed Jun 7, 2018, issued as US 10,842,823
Divisional of 14/418,557, filed Jan 30, 2015, issued as US 10,016,463
National stage entry of PCTUS2013052700, filed Jul 30, 2013
National stage entry of PCTUS2013052700, filed Jul 30, 2013
Divisional of 14/418,557, filed Jan 30, 2015, issued as US 10,016,463
National stage entry of PCTUS2013052700, filed Jul 30, 2013
Continuation of 16/002,250, filed Jun 7, 2018, issued as US 10,842,823
Divisional of 14/418,557, filed Jan 30, 2015, issued as US 10,016,463
National stage entry of PCTUS2013052700, filed Jul 30, 2013
Jul 30, 2013 + 20y = Jul 30, 2033
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 18/535,745 · US 12,310,992
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 12,310,992: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12310992Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.